Sharechat Logo

Acurity sees improvement in 1H earnings on cost-cutting measures

Monday 14th October 2013

Text too small?

Acurity Health Group, the private hospital group formerly known as Wakefield Health, boosted underlying earnings by as much as 23 percent as it managed to strip out costs faster than its revenue declined.

The Wellington-based company says its underlying earnings were between $3.3 million and $3.5 million in the six months ended Sept. 30, up by between 17 percent and 23 percent from a year earlier. Net profit was between $3.9 million and $4.1 million, with a "significant component" coming from a revaluation of interest rate swaps. The company reported first-half net profit of $2.4 million in 2012.

"The group's revenue for the first six months of the year is down slightly on the corresponding period for the previous year but continuing focus on expenses has resulted in the improvement in the underlying net earnings," it said in a statement.

Acurity's biggest shareholders, the Stewart family and Royston Hospital Trust Board, took control of the company in September last year, pooling their investments into a joint vehicle called Medusa.

The shares rose 2.3 percent to $4.02 today, having shed 21 percent this year.

The full results and dividend declaration will be announced on Nov. 4.

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors